Duarte MJ, Romero FS, Espinosa LRF, Graciela SRG

Language: Spanish
References: 66
Page: 318-329
PDF size: 520.68 Kb.

ABSTRACT

Type 2 diabetes mellitus currently comprises one of the diseases with the highest prevalence. The association that presents with the appearance of some types of cancer is worrisome given this prevalence. There is a solid body of observational evidence for this association, but the weight of each of the factors that seem to be involved is not conclusive and the information so far is contradictory. Although the treatment prescribed in the control of diabetics appears to have influence on the appearance of cancer, currently still there is no formal consensus to issue some kind of contraindication. Cancer should be considered one of the chronic complications of diabetes, so it will always be prudent to start screening in all diabetics in this aspect.

REFERENCES

1. Chowdhury TA. Diabetes and cancer. QJM 2010;103:905- 915.

2. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cáncer. Endocr Relat Cancer 2009;16:1103-1123.

3. Wilson EB, Maher HC. Cancer and tuberculosis with some comments on cancer and other diseases. Am J Cancer 1932;16:227-250.

4. Joslin EP, Lombard HL, Burrows RE, Manning MD. Diabetes and cancer. N Engl J Med 1959;260:486-488.

5. Buysschaert M, Sadikot S. Diabetes and cancer: a 2013 synopsis. Diabetes Metab Syndr Clin Res Rev 2013;7:247-250.

6. Swerdlow AJ, Laing SP, Qiao Z, Slater SD, et al. Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. Br J Cancer 2005;92;2070-2075.

7. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001;131:3109-3120.

8. Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-I-like mitogenic and antiapoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 2009;25:41-49.

9. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009;52:1732-1744.

10. Jonasson JM, Ljung R, Talbäck M, et al. Insulin glargine use and short-term incidence of malignancies–a population- based follow-up study in Sweden. Diabetologia 2009;52:1745-1754.

11. Colhoun HM, SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009;52:1755-1765.

12. Inoue M, Iwasaki M, Otani T, Sasazuki S, et al. Diabetes mellitus and the risk of cancer, results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006;166:1871-1877.

13. Zendehdel K, Nyrén O, Ostenson CG, Adami HO, et al. Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 2003;95:1797-1800.

14. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004;159:1160-1167.

15. Peairs KS, Barone BB, Snyder CF, Yeh HC, et al. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol 2011;29:40-46.

16. Barone BB, Yeh HC, Snyder CF, Peairs KS, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008;300:2754-2764.

17. Handelsman Y, Leroith D, Bloomgarden ZT, Dagogo-Jack S, et al. Diabetes and cancer–an AACE/ACE consensus statement. Endocr Pract 2013;19:675-693.

18. Yang X, et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes 2010;59:1254-1260.

19. Siddiqui AA, Maddur H, Naik S, Cryer B. The association of elevated HbA1c on the behavior of adenomatous polyps in patients with type-II diabetes mellitus. Dig Dis Sci 2008;53:1042-1047.

20. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010;33:1674-1685.

21. Morris PG, Hudis CA, Giri D, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila) 2011;4:1021-1029.

22. Subbaramaiah K, Howe LR, Bhardwaj P, Du B, et al. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila) 2011;4:329-346.

23. Adams TD, Stroup AM, Gress RE, et al. Cancer incidence and mortality after gastric bypass surgery. Obesity (Silver Spring) 2009;17:796-802.

24. Zhang H, Fagan DH, Zeng X, Freeman KT, et al. Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene 2010;29:2517-2527.

25. Arteaga CL, Kitten LJ, Coronado EB, et al. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 1989;84:1418-1423.

26. Arteaga CL, Osborne CK. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res 1989;49:6237-6241.

27. Del Giudice ME, Fantus IG, Ezzat S, McKeown-Eyssen G, et al. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 1998;47:111-120.

28. Hirose K, Toyama T, Iwata H, Takezaki T, et al. Insulin, insulinlike growth factor-I and breast cancer risk in Japanese women. Asian Pac J Cancer Prev 2003;4:239-246.

29. Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009;52:2499-2506.

30. Buysschaert M, Buysschaert B. Insulines et cancers (y compris du sein): un synopsis de quatre e’tudes contradictoires. Louvain Med 2009;128:265-269.

31. Dejgaard A, Lynggaard H, Rastam J, et al. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a metaanalysis. Diabetologia 2009;52:2507-2512.

32. Chang CH, Toh S, Lin JW, et al. Cancer risk associated with insulin glargine among adult type 2 diabetes patients-a nationwide cohort study. PLoS One 2011;6:21368.

33. Ruiter R, Visser LE, van Herk-Sukel MPP, et al. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 2012;55:51-62.

34. Colmers IN, Bowker SL, Tjosvold LA, Johnson JA. Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies Diabetes Metabo 2012;38:485-506.

35. Nicolucci A. Epidemiological aspects of neoplasms in diabetes. Acta Diabetologica 2010;47:87-95.

36. Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidem Biomar Prev 2006;15:2056-2062.

37. Hong SK, Oh JJ, Byun SS, Hwang SI, et al. Impact of diabetes mellitus on the detection of prostate cancer via contemporary multi (≥ 12)-core prostate biopsy. Prostate 2012;72:51-57.

38. Simon D, Charles MA, Lahlou N, Nahoul K, et al. Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: a 3-month randomized placebo-controlled trial. Diabetes Care 2001;24:2149-2151.

39. Frayling TM, Colhoun H, Florez JC. A genetic link between type 2 diabetes and prostate cancer. Diabetologia 2008;51:1757-1760.

40. Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose and risk of cause-specific death. N Engl J Med 2011;364:829-841.

41. Stattin P, Björ O, Ferrari P, et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care 2007;30:561-567.

42. Stocks T, Rapp K, Bjørge T, et al. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med 2009;6:1000201.

43. Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 2011;54:25-31.

44. Stefansdottir G, Zoungas S, Chalmers J, et al. Intensive glucose control and risk of cancer in patients with type 2 diabetes. Diabetologia 2011;54:1608-1614.

45. Gerstein HC. Does insulin therapy promote, reduce, or have a neutral effect on cancers. J Am Med Assoc 2010;303:446-447.

46. Khaw KT, Wareham N, Bingham S, et al. Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European Prospective Investigation into cancer-Norfolk study. Cancer Epidemiol Biomarkers Prev 2004;13:915-919.

47. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-1033.

48. Pollak MN. Insulin, insulin-like growth factors, insulin resistance, and neoplasia. Am J Clin Nutr 2007;86:820-821.

49. Le Roith D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med 1997;336:633-640.

50. Ruiter R, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care 2012;35:119-124.

51. Yang X, So WY, Ma RC, Kong AP, et al. Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry Diabetes Care 2011;34:375-380.

52. Skinner HD, et al. Metformin use and improved response to therapy in rectal cancer Cancer Med 2013;2:99-107.

53. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycindependent translation initiation in breast cancer cells. Cancer Res 2007;67:10804-10812.

54. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 2009;8:88-96.

55. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009;69:7507-7511.

56. Johnson JA, Gale EA. Diabetes, insulin use, and cancer risk: are observational studies part of the solution–or part of the problem? Diabetes 2010;59:1129-1131.

57. Joh HK, Willett WC, Cho E. Type 2 diabetes and the risk of renal cell cancer in women. Diabetes Care 2011;34:1552- 1556.

58. Habel LA, Danforth KN, Quesenberry CP, Capra A, et al. Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes. Diabetes Care 2013;36:3953-3960.

59. Renehan A, Smith S, Kirkman MS. Linking diabetes and cancer: a consensus on complexity. Lancet 2010;375:2201-2202.

60. Jee SH, Ohrr H, Sull JW, et al. Fasting serum glucose level and cancer risk in Korean men and women. J Am Med Assoc 2005;293:194-202.

61. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53 and IGF-independent mechanism. J Biol Chem 1997;272:12181-12188.

62. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 2012;7:33411.

63. Colmers IN, Bowker SL, Johnson JA. Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab 2012;38:475- 484.

64. Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ 2012;184:675-683.

65. Azoulay L, Yin H, Filion KB, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 2012;344:3645.

66. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011;34:916-922.